MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician

다국어 초록 (Multilingual Abstract)

Since the first descriptions of their active functions more than ten years ago, small non-coding RNA species termed microRNA (miRNA) have emerged as essential regulators in a broad range of adaptive and maladaptive cellular processes.
With an exceptionally rapid pace of discovery in this field, the dysregulation of many individual miRNAs has been implicated in the development and progression of various cardiovascular diseases. MiRNA are also expected to play crucial regulatory roles in the progression of pulmonary vascular diseases such as pulmonary hypertension (PH), yet direct insights in this field are only just emerging. This review will provide an overview of pulmonary hypertension and its molecular mechanisms, tailored for both basic scientists studying pulmonary vascular biology and physicians who manage PH in their clinical practice. We will describe the pathobiology of pulmonary hypertension and mechanisms of action of miRNA relevant to this disease. Moreover, we will summarize the potential roles of miRNA as biomarkers and therapeutic targets as well as future strategies for defining the cooperative actions of these powerful effectors in pulmonary vascular disease.

참고문헌 (Reference)

1 Doench JG, "siRNAs can function as miRNAs" 17 : 438-442, 2003

2 Yang S, "miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling" 302 : L521-L529, 2012

3 Simonneau G, "Updated clinical classification of pulmonary hypertension" 54 (54): S43-S54, 2009

4 Mittelbrunn M, "Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells" 2 : 282-, 2011

5 Ma L, "Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model" 28 : 341-347, 2010

6 Montgomery RL, "Therapeutic advances in MicroRNA targeting" 57 : 1-7, 2011

7 Guo L, "The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C" 59 : 1006-1013, 2012

8 Krutzfeldt J, "Silencing of microRNAs in vivo with ‘antagomirs’" 438 : 685-689, 2005

9 Zhang Y, "Secreted monocytic miR-150 enhances targeted endothelial cell migration" 39 : 133-144, 2010

10 Urbich C, "Role of microRNAs in vascular diseases, inflammation, and angiogenesis" 79 : 581-588, 2008

11 Courboulin A, "Role for miR-204 in human pulmonary arterial hypertension" 535-548, 2011

12 Brodersen P, "Revisiting the principles of microRNA target recognition and mode of action" 10 : 141-148, 2009

13 Zhao YD, "Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease" 96 : 442-450, 2005

14 Rhodes CJ, "Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension" 294-302, 2013

15 Farber HW, "Pulmonary arterial hypertension" 351 : 1655-1665, 2004

16 McLaughlin VV, "Pulmonary arterial hypertension" 36 : 461-517, 2011

17 Lewis BP, "Prediction of mammalian microRNA targets" 115 : 787-798, 2003

18 Eddahibi S, "Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease" 108 : 1839-1844, 2003

19 Cheng CJ, "Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing" 9 : 1481-1488, 2012

20 Bockmeyer CL, "Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression" 31 : 764-772, 2012

21 Small EM, "Pervasive roles of microRNAs in cardiovascular biology" 469 : 336-342, 2011

22 Tuder RM, "Pathology of pulmonary arterial hypertension" 30 : 376-385, 2009

23 Chan SY, "Pathogenic mechanisms of pulmonary arterial hypertension" 44 : 14-30, 2008

24 Carthew RW, "Origins and mechanisms of miRNAs and siRNAs" 136 : 642-655, 2009

25 Esteller M, "Non-coding RNAs in human disease" 12 : 861-874, 2011

26 Babar IA, "Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma" 109 : E1695-E1704, 2012

27 Newman JH, "Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred" 345 : 319-324, 2001

28 Friedman RC, "Most mammalian mRNAs are conserved targets of microRNAs" 19 : 92-105, 2009

29 Jeffery TK, "Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension" 45 : 173-202, 2002

30 Vickers KC, "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins" 13 : 423-433, 2011

31 Bartel DP, "MicroRNAs : target recognition and regulatory functions" 136 : 215-233, 2009

32 Chan SY, "MicroRNA-210 : a unique and pleiotropic hypoxamir" 9 : 1072-1083, 2010

33 Parikh VN, "MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension : results of a network bioinformatics approach" 125 : 1520-1532, 2012

34 Thum T, "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts" 456 : 980-984, 2008

35 Care A, "MicroRNA-133 controls cardiac hypertrophy" 613-618, 2007

36 Liu N, "MicroRNA regulatory networks in cardiovascular development" 18 : 510-525, 2010

37 Filipowicz W, "Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?" 9 : 102-114, 2008

38 Schermuly RT, "Mechanisms of disease : pulmonary arterial hypertension" 8 : 443-455, 2011

39 Mercer TR, "Long non-coding RNAs : insights into functions" 10 : 155-159, 2009

40 Brock M, "Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway" 104 : 1184-1191, 2009

41 Pullamsetti SS, "Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension" 185 : 409-419, 2012

42 Kuwabara Y, "Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage" 4 : 446-454, 2011

43 Frid MG, "Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage" 168 : 659-669, 2006

44 Maynard MA, "Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma" 19 : 1396-1406, 2005

45 White K, "Holding our breath : the emerging and anticipated roles of microRNA in pulmonary hypertension" 2 : 278-290, 2012

46 International PPH Consortium, "Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension" 26 : 81-84, 2000

47 Adams JM, "HIF-1 : a key mediator in hypoxia" 96 : 19-28, 2009

48 Shimoda LA, "HIF and the lung : role of hypoxia-inducible factors in pulmonary development and disease" 183 : 152-156, 2011

49 Pegtel DM, "Functional delivery of viral miRNAs via exosomes" 107 : 6328-6333, 2010

50 Valadi H, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells" 9 : 654-659, 2007

51 Archer SL, "Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension : a basis for excessive cell proliferation and a new therapeutic target" 121 : 2661-2671, 2010

52 Budhiraja R, "Endothelial dysfunction in pulmonary hypertension" 109 : 159-165, 2004

53 Fabani MM, "Efficient inhibition of miR-155 function in vivo by peptide nucleic acids" 38 : 4466-4475, 2010

54 Caruso P, "Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline" 30 : 716-723, 2010

55 Wang V, "Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells" 65 : 3299-3306, 2005

56 Abdellatif M, "Differential expression of microRNAs in different disease states" 110 : 638-650, 2012

57 Lawrie CH, "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma" 141 : 672-675, 2008

58 Zernecke A, "Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection" 2 : ra81-, 2009

59 Lourenco AP, "Current pathophysiological concepts and management of pulmonary hypertension" 155 : 350-361, 2012

60 Lewis BP, "Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets" 120 : 15-20, 2005

61 Xu J, "Circulating microRNAs: novel biomarkers for cardiovascular diseases" 90 : 865-875, 2012

62 Creemers EE, "Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?" 110 : 483-495, 2012

63 Fichtlscherer S, "Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?" 31 : 2383-2390, 2011

64 Mitchell PS, "Circulating microRNAs as stable blood-based markers for cancer detection" 105 : 10513-10518, 2008

65 Lennox KA, "Chemical modification and design of anti-miRNA oligonucleotides" 18 : 1111-1120, 2011

66 Chen X, "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases" 18 : 997-1006, 2008

67 Morrell NW, "Cellular and molecular basis of pulmonary arterial hypertension" 54 (54): S20-S31, 2009

68 Weidemann A, "Biology of HIF-1alpha" 15 : 621-627, 2008

69 Archer SL, "Basic science of pulmonary arterial hypertension for clinicians : new concepts and experimental therapies" 121 : 2045-2066, 2010

70 Hammond SM, "Argonaute2, a link between genetic and biochemical analyses of RNAi" 293 : 1146-1150, 2001

71 Arroyo JD, "Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma" 108 : 5003-5008, 2011

72 Brock M, "AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension" 26 : 2012

73 Alexander RP, "Annotating non-coding regions of the genome" 11 : 559-571, 2010

74 Kim J, "An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension" 19 : 74-82, 2013

75 Caruso P, "A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples" 111 : 290-300, 2012